Dr. Keisha Hylton-Rodić is a U.S. patent attorney and Founder of Hylton-Rodic Law, an IP boutique based in Washington, D.C. She holds a Ph.D. in Organic Chemistry and is registered to practice before the United States Patent and Trademark Office (USPTO).  

Dr. Hylton-Rodić advises European and global life sciences companies on navigating the complexities of U.S. patent law with precision and efficiency. Her practice focuses on strategic IP portfolio development and optimization for biotech and pharmaceutical innovators—helping clients build, protect, and leverage their U.S. and international patent assets.  

She regularly counsels clients on freedom-to-operate analyses, API clearances, due diligence, patentability, infringement, and validity assessments, with a pragmatic approach that aligns with commercial objectives and regulatory realities.  

Her technical expertise spans small molecules, biologics, formulations, and delivery systems—including injectables, inhalation forms, transdermals, and oral dosage technologies—as well as related materials and manufacturing chemistry.   

What sets Hylton-Rodic Law apart is its combination of deep scientific understanding, U.S. regulatory insight, and partner-level responsiveness—delivering the caliber of representation expected from large U.S. firms, with the agility and cost-efficiency of a focused boutique.  

Specialties: U.S. patent strategy and prosecution, portfolio management, due diligence, freedom-to-operate and risk mitigation, infringement and validity opinions, life sciences IP, biotechnology, pharmaceuticals.